SCHEMBL1660408

SCHEMBL1660408

Oc1cccc2c1CCC2CF

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.62
ESR2 Q92731 1/20 0.62
ADRA2A P08913 3/20 0.49
ADRA2B P18089 3/20 0.49
ADRA2C P18825 3/20 0.49
ADRA1D P25100 3/20 0.49
ADRA1A P35348 3/20 0.49
ADRA1B P35368 3/20 0.49
DRD2 P14416 4/20 0.45
CYP1A1 P04798 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2E1 P05181 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C8 P10632 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2A6 P11509 1/20 0.44
CYP19A1 P11511 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP4B1 P13584 1/20 0.44
CYP2B6 P20813 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24394021 0.82 ESR1 (0.62) ESR1ESR2ADRA2AADRA2BADRA2C
SCHEMBL1660867 0.82 ESR1 (0.62) ESR1ESR2ADRA2AADRA2BADRA2C
SCHEMBL3292547 0.82 ADRA2A (0.72) ESR1ESR2ADRA2AADRA2BADRA2C
SCHEMBL3020498 0.79 ESR1 (0.59) ESR1ESR2ADRA2AADRA2BADRA2C
SCHEMBL32679917 0.78 ESR1 (0.57) ESR1ESR2ADRA2AADRA2BADRA2C
SCHEMBL7776691 0.74 ESR1 (0.53) ESR1ESR2ADRA2ADRD2SIGMAR1
SCHEMBL9534010 0.73 ESR1 (0.51) ESR1ESR2DRD2CYP1A1CYP1A2
SCHEMBL13518633 0.73 ESR1 (0.51) ESR1ESR2DRD2CYP1A1CYP1A2
SCHEMBL9549176 0.72 ADRA2A (0.58) ESR1ESR2ADRA2AADRA2BADRA2C
SCHEMBL8816707 0.72 ADRA2A (0.58) ESR1ESR2ADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307394-A2 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME Amorepacific Corporation (KR) 2011-04-13 EP disclosed
WO-2010002209-A2 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AMOREPACIFIC CORPORATION (KR) 2010-01-07 WO disclosed